Publications

Rates of opioid use, dependence, and overdose in the United States are reaching epidemic-level proportions. In this action plan, DPA outlines a robust response focused on effective treatment, harm reduction, prevention...
Synthetic opioids refer to a category of novel psychoactive substances (NPS) that are either known to be opiates or have opiate-like effects. Fentanyl is perhaps the most well-known of the synthetic opioids, since...
Marijuana Facts is intended for people seeking answers to some of the most common questions about marijuana use, its effects, and the rapidly-shifting legal landscape. This booklet addresses 15 frequently-asked...
New York became the 23rd state to roll out its medical marijuana program on January 7, 2016. The law has been criticized as being one of the most restrictive and burdensome programs in the country. This report, an...
The Ally is the Drug Policy Alliance's tri-annual member newsletter. We love to hear from our members – if you have questions or feedback, contact The Ally at newsletter [at] drugpolicy [dot] org.
"Racial Disparities in Marijuana Arrests in Virginia (2003-2013)" reveals that marijuana possession arrests in Virginia have increased dramatically in recent years despite a nationwide trend in favor of...
In November 2012, voters in Washington and Colorado approved the first two laws in the U.S. to end marijuana prohibition and legally regulate marijuana production, distribution and sales. In December 2012, marijuana...
Above the Law: An Investigation of Civil Asset Forfeiture Abuses in California is a multi-year, comprehensive look at asset forfeiture abuses in California that reveals the troubling extent to which law enforcement...
The federal Drug Enforcement Administration (DEA) has existed for more than 40 years, but little attention has been given to the role the agency has played in fueling mass incarceration, racial disparities and other...
See the interactive 2015 Annual Report. We’re changing the conversation about the war on drugs and bringing about a new world of opportunities for drug policy reform. There is now, for the first time, a critical...
Page 1 of 5